Literature DB >> 20442298

Thrombin regulates the metastatic potential of human rhabdomyosarcoma cells: distinct role of PAR1 and PAR3 signaling.

Marcin Wysoczynski1, Rui Liu, Magda Kucia, Justyna Drukala, Mariusz Z Ratajczak.   

Abstract

We observed that human rhabdomyosarcoma (RMS) cells highly express a tissue factor that promotes thrombin formation, which indirectly and directly affects RMS progression. First, we found that thrombin activates platelets to generate microvesicles (PMV), which transfer to RMS cells' alpha2beta3 integrin and increase their adhesiveness to endothelial cells. Accordingly, RMS cells covered with PMVs showed higher metastatic potential after i.v. injection into immunodeficient mice. Furthermore, PMVs activate mitogen-activated protein kinase (MAPK)p42/44 and AKT to chemoattract RMS cells. We also found that RMS cells express functional protease-activated receptor-1 (PAR1) and PAR3 and respond to thrombin stimulation by MAPKp42/44 and MAPKp38 phosphorylation. To our surprise, thrombin did not affect RMS proliferation or survival; it inhibited the chemotactic and adhesive properties of RMS cells. However, when PAR1-specific agonist thrombin receptor-activating peptide 6 was used, which does not activate PAR3, selective PAR1 stimulation enhanced RMS proliferation. To learn more on the role of PAR1 and PAR3 antagonism in RMS proliferation and metastasis, we knocked down both receptors by using a short hairpin RNA strategy. We found that although thrombin does not affect growth of PAR1(-/-) cells, it stimulated the proliferation of PAR3(-/-) cells. More importantly, PAR3(-/-) cells, in contrast to PAR1(-/-) ones, formed larger tumors in immunodeficient mice. We conclude that thrombin is a novel underappreciated modulator of RMS metastasis and that we have identified a novel role for PAR3 in thrombin signaling. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20442298      PMCID: PMC2896479          DOI: 10.1158/1541-7786.MCR-10-0019

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  51 in total

1.  Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas.

Authors:  Katarzyna Grymula; Maciej Tarnowski; Marcin Wysoczynski; Justyna Drukala; Frederic G Barr; Janina Ratajczak; Magdalena Kucia; Mariusz Z Ratajczak
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

2.  Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer.

Authors:  Joseph Sgouros; Anthony Maraveyas
Journal:  Acta Oncol       Date:  2008       Impact factor: 4.089

3.  Tethered ligand-derived peptides of proteinase-activated receptor 3 (PAR3) activate PAR1 and PAR2 in Jurkat T cells.

Authors:  Kristina K Hansen; Mahmoud Saifeddine; Morley D Hollenberg
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

4.  The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma.

Authors:  J W Blom; S Osanto; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2004-10       Impact factor: 5.824

5.  Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis.

Authors:  Liang Hu; Merlin Lee; Wendy Campbell; Roman Perez-Soler; Simon Karpatkin
Journal:  Blood       Date:  2004-07-20       Impact factor: 22.113

6.  Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis.

Authors:  Xiaoli Shi; Beena Gangadharan; Lawrence F Brass; Wolfram Ruf; Barbara M Mueller
Journal:  Mol Cancer Res       Date:  2004-07       Impact factor: 5.852

Review 7.  Role of tissue factor in cancer.

Authors:  Raj S Kasthuri; Mark B Taubman; Nigel Mackman
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

8.  Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: therapeutic implications.

Authors:  Marcin Wysoczynski; Dong-Myung Shin; Magda Kucia; Mariusz Z Ratajczak
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396

9.  Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma.

Authors:  Graham J Caine; Gregory Y H Lip; Paul S Stonelake; Peter Ryan; Andrew D Blann
Journal:  Thromb Haemost       Date:  2004-07       Impact factor: 5.249

10.  Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222.

Authors:  Liang Hu; Sherif Ibrahim; Cynthia Liu; Jeffrey Skaar; Michele Pagano; Simon Karpatkin
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

View more
  11 in total

1.  Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts.

Authors:  Maciej Tarnowski; Katarzyna Grymula; Rui Liu; Joanna Tarnowska; Justyna Drukala; Janina Ratajczak; Robert A Mitchell; Mariusz Z Ratajczak; Magda Kucia
Journal:  Mol Cancer Res       Date:  2010-09-22       Impact factor: 5.852

Review 2.  Introduction to haemostasis from a pharmacodynamic perspective.

Authors:  Cornelis Kluft; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 3.  GPCRs and cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

4.  Pro-Angiogenic Actions of CMC-Derived Extracellular Vesicles Rely on Selective Packaging of Angiopoietin 1 and 2, but Not FGF-2 and VEGF.

Authors:  Marcin Wysoczynski; Asif Pathan; Joseph B Moore; Talha Farid; Jae Kim; Marjan Nasr; Yi Kang; Hong Li; Roberto Bolli
Journal:  Stem Cell Rev Rep       Date:  2019-08       Impact factor: 5.739

5.  Proteinase-activated receptors differentially modulate in vitro invasion of human pancreatic adenocarcinoma PANC-1 cells in correlation with changes in the expression of CDC42 protein.

Authors:  Liora Segal; Liora S Katz; Monica Lupu-Meiri; Hagit Shapira; Judith Sandbank; Marvin C Gershengorn; Yoram Oron
Journal:  Pancreas       Date:  2014-01       Impact factor: 3.327

6.  A Role for Protease Activated Receptor Type 3 (PAR3) in Nociception Demonstrated Through Development of a Novel Peptide Agonist.

Authors:  Juliet Mwirigi; Moeno Kume; Shayne N Hassler; Ayesha Ahmad; Pradipta R Ray; Changyu Jiang; Alexander Chamessian; Nakleh Mseeh; Breya P Ludwig; Benjamin D Rivera; Marvin T Nieman; Thomas Van de Ven; Ru-Rong Ji; Gregory Dussor; Scott Boitano; Josef Vagner; Theodore J Price
Journal:  J Pain       Date:  2021-01-09       Impact factor: 5.383

Review 7.  Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond.

Authors:  Sven Danckwardt; Matthias W Hentze; Andreas E Kulozik
Journal:  J Mol Med (Berl)       Date:  2013-08-17       Impact factor: 4.599

8.  Induction of a tumor-metastasis-receptive microenvironment as an unwanted and underestimated side effect of treatment by chemotherapy or radiotherapy.

Authors:  Mariusz Z Ratajczak; Tomasz Jadczyk; Gabriela Schneider; Sham S Kakar; Magda Kucia
Journal:  J Ovarian Res       Date:  2013-12-27       Impact factor: 4.234

Review 9.  Exosomes: an overview of biogenesis, composition and role in ovarian cancer.

Authors:  Allison Beach; Huang-Ge Zhang; Mariusz Z Ratajczak; Sham S Kakar
Journal:  J Ovarian Res       Date:  2014-01-25       Impact factor: 4.234

Review 10.  Does it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer?

Authors:  Mariusz Z Ratajczak; Malwina Suszynska; Magda Kucia
Journal:  Clin Transl Med       Date:  2016-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.